Influenza virus vaccine, inactivated FDA Alerts
The FDA Alerts below may be specifically about influenza virus vaccine, inactivated or relate to a group or class of drugs which include influenza virus vaccine, inactivated.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings.
Recent FDA Alerts for influenza virus vaccine, inactivated
Afluria (CSL Ltd.) Influenza Virus Vaccine: Label Change - Risk of Fever and Febrile Seizure
ISSUE: FDA updated the Warnings and Precautions sections of the Prescribing Information for Afluria to inform healthcare professionals that the Afluria vaccine has been associated with an increased incidence of fever and febrile seizure among young children reported in Australia, mainly among those less than 5 years of age.
BACKGROUND: FDA announced the approved vaccines for the 2010-2011 influenza season in the United States. The brand names and manufacturers for the upcoming season’s vaccines are: Afluria, CSL Limited; Agriflu, Novartis Vaccines and Diagnostics; Fluarix, GlaxoSmithKline Biologicals; FluLaval, ID Biomedical Corporation; FluMist, MedImmune Vaccines Inc.; Fluvirin, Novartis Vaccines and Diagnostics Limited; and Fluzone and Fluzone High-Dose, Sanofi Pasteur Inc.
The available data suggest that the increased rates of fever and febrile seizure are only associated with the Southern Hemisphere formulation of CSL’s vaccine. The available data regarding the safety of other influenza vaccines for children used in the Southern Hemisphere do not suggest an increased rate of fever or febrile seizure. FDA is requiring CSL Limited to conduct a study of Afluria in children to obtain additional information regarding the febrile events that were seen in the Southern Hemisphere. CSL Limited will not be supplying the United States with the 0.25 milliliter single-dose, prefilled syringes, which are used in very young children. The 0.5 milliliter single-dose, prefilled syringes and 5 milliliter multi-dose vials will be distributed.
RECOMMENDATION: Vaccines for the 2010-2011 influenza season are approved by FDA for the prevention of influenza in children, adolescents, and adults, including the elderly. There are several vaccines approved by FDA available in both nasal spray and injectable (“shot”) forms. Because the influenza viruses that cause people to get sick can change, each year's vaccine may be different from the previous year. Therefore, it is important to get the influenza vaccine every year.
Various investigations into the cause(s) of the febrile seizures seen with Afluria vaccine are still ongoing. FDA is collaborating with Australia’s regulatory authority, other international regulatory counterparts, and CSL to obtain additional information, stay apprised and take part in the investigations. FDA, in collaboration with CDC, will closely monitor the continued safety of all influenza vaccines.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the Vaccine Adverse Events Reporting System, a national vaccine safety surveillance program co-sponsored by the Centers for Disease Control and Prevention and the Food and Drug Administration.
[07/30/2010 - Q&As - FDA]
[07/30/2010 - News Release - FDA]
[07/30/2010 - Product Page - FDA]
[07/30/2010 - Package Insert - CSL]
More influenza virus vaccine, inactivated resources
- FluLaval PF Prefilled Syringe 2024-2025 injection Consumer Information
- FluLaval PF Quadrivalent 2022-2023 injection Consumer Information
- Fluad PF Prefilled Syringe 2024-2025 injection Consumer Information
- Fluad Quadrivalent PF 2022-2023 injection Consumer Information
- Fluarix PF Prefilled Syringe 2024-2025 injection Consumer Information
- Fluarix PF Quadrivalent 2022-2023 injection Consumer Information
- Flublok PF Prefilled Syringe 2024-2025 injection Consumer Information
- Flublok Quadrivalent 2022-2023 injection Consumer Information
- Flucelvax 2024-2025 injection Consumer Information
- Flucelvax PF Quadrivalent 2022-2023 injection Consumer Information
- Flucelvax Quadrivalent 2022-2023 injection Consumer Information
- Fluzone 2024-2025 injection Consumer Information
- Fluzone High-Dose Quadrivalent PF 2022-2023 injection Consumer Information
- Fluzone PF Quadrivalent 2022-2023 injection Consumer Information
- Fluzone Quadrivalent 2022-2023 injection Consumer Information
- Influenza virus vaccine injection Consumer Information
- FluLaval Quadrivalent 2015-2016 Formula Advanced Consumer Information
- Fluad 2017-2018 Formula Advanced Consumer Information
- Fluarix Quadrivalent 2013-2014 Formula Advanced Consumer Information
- Fluarix Quadrivalent 2015-2016 Formula Advanced Consumer Information
- Flublok 2015-2016 Formula Advanced Consumer Information
- Flucelvax 2015-2016 Formula Advanced Consumer Information
- Flulaval Quadravalent 2013-2014 Season Advanced Consumer Information
- Fluvirin 2015-2016 Formula Advanced Consumer Information
- Fluzone 2013-2014 Formula Advanced Consumer Information
- Fluzone 2015-2016 Formula Advanced Consumer Information
- Fluzone High Dose 2015-2016 Formula Advanced Consumer Information
- Fluzone Intradermal Quadrivalent 2014-2015 Formula Advanced Consumer Information
- Fluzone Intradermal Quadrivalent 2015-2016 Formula Advanced Consumer Information
- Influenza virus vaccine Advanced Consumer Information
- Influenza virus vaccine recombinant Advanced Consumer Information
- Influenza virus vaccine, adjuvanted Advanced Consumer Information
- Influenza Vaccine Recombinant (Seasonal) AHFS DI Monograph
- Influenza Virus Vaccine Inactivated AHFS DI Monograph
- Influenza Virus Vaccine (Inactivated) Consumer Information
- Fluzone Northern Hemisphere Prescribing Information
- Fluzone Quadrivalent Southern Hemisphere. Prescribing Information